China Pharma's Candesartan Hypertension Product Passes The Quality And Efficacy Consistency Evaluation Of Generic Drugs
Portfolio Pulse from Benzinga Newsdesk
China Pharma Holdings, Inc. (NYSE:CPHI) announced that its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., has received approval for its candesartan tablets from the National Medical Products Administration of China. The approval indicates that the tablets have passed the quality and efficacy consistency evaluation of generic drugs. Candesartan is used for primary hypertension and is a flagship product of China Pharma. The approval allows the company to participate in China's national centralized procurement, enhancing its competitiveness in government procurement.
August 09, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
China Pharma's candesartan tablets have received approval from the National Medical Products Administration of China, indicating a positive impact on the company's competitiveness in government procurement.
The approval of China Pharma's candesartan tablets by the National Medical Products Administration of China is a significant milestone for the company. This not only validates the quality and efficacy of the drug but also allows the company to participate in China's national centralized procurement, which could potentially lead to increased sales and revenue. Therefore, this news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100